
|Articles|April 12, 2018
Ipsos Healthcare Releases Pan-Cancer Testing Monitor in Australia
Advertisement
Ipsos Healthcare-the global healthcare business of Ipsos-announced the expansion of its syndicated Pan-Cancer Testing Monitor (PCTM) to the Australian market.
The study gathers insights from medical oncologists and pathologists on topics such as awareness and current utilization of pan-cancer tests, perceived advantages and disadvantages, and drivers and barriers to use. In addition, it incorporates de-identified patient record forms for patients who were recently tested with a pan-cancer test.
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Bayer Shares Briefly Dip After Activist Investor Offloads Millions of Dollars in Company Stock
2
Pharmaceutical Executive Daily: FDA Issues Warning Letter to ImmunityBio
3
Pharma M&A Roundup: Merck to Acquire Terns Pharmaceuticals, Shionogi to Acquire 50% of Apnimed’s Ownership of Shionogi-Apnimed Sleep Science
4
FDA Sends Warning Letter to ImmunityBio for Misleading Claims in Advertisement
5




